Twist Bioscience Launches 96-Plex Library Prep Kit for Low Pass High Throughput Next-Generation Sequencing
December 20 2021 - 7:00AM
Business Wire
-- Further enables customers to convert from
SNP microarray to NGS-based approach --
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of synthetic DNA using
its silicon platform, today announced the launch of the Twist
96-Plex Library Prep Kit, a high-performance, cost-effective
preparation kit for next-generation sequencing (NGS). Recently, new
methods in genotyping by sequencing (GBS) have unlocked the
potential for NGS to improve not only data quality and quantity but
also deliver significant improvements in lab workflows and reduce
sample prep costs.
"With the 96-Plex Library Prep Kit, we were able to discover a
statistically significant genetic association to Westie lung
disease, a canine model for human idiopathic pulmonary fibrosis
(IPF) that was missed with microarray technology,” said Matt
Huentelman, Associate Professor of Neurogenomics, TGen.
Sri Kosuri, Founder and CEO of Octant commented, “We needed a
robust, scalable, and low touch method for verifying full plasmid
sequences…ideally, one that would not require a huge investment in
labor and capital. We found the Twist 96-Plex Library Prep
Kit!”
Library preparation is a major bottleneck for sequencing
workflows, from both a timing and cost perspective. With the
ability to multiplex up to 960 samples upfront and combining
best-in-class enzymes with optimized oligos and buffer conditions,
the Twist 96-Plex Library Preparation Kit (formerly RIPTIDE from
iGenomX) limits the reagent volume required for later reactions and
reduces the hands-on processing for each sample. The Twist 96-Plex
Library Preparation Kit provides more complete genetic information
than microarrays, which results in increased statistical power for
genotyping studies and enables researchers to obtain greater
biological insights at a higher scale and lower cost.
"96-Plex Library Prep Kit-enabled genotyping is a significant
advancement over microarrays. The approach provides a greater
density of genomic markers throughout the genome at a significantly
reduced cost,” said Ali Torkamani, director, Genomics and Genome
Informatics, Scripps Research Translational Institute, Associate
Professor, Scripps Research.
“The Twist 96-Plex Library Prep Kit includes a robust PCR-like
workflow for ultra-high throughput library construction that allows
customers to use a small amount of sequencing data to generate
high-quality genotype calls across the entire genome. Following the
acquisition of iGenomX, we ‘Twistified’ the product which we
believe will be instrumental in enabling customers to conduct
studies involving hundreds to thousands of samples, whether
screening traits for seed selection or verifying the sequence of
plasmid colonies,” said Emily M. Leproust, Ph.D., CEO and
co-founder of Twist Bioscience.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including without limitation the anticipated cost savings
resulting from using the Twist 96-Plex Library Prep Kit, are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive; the retention
of employees of acquired companies and the ability of Twist
Bioscience to successfully integrate acquired companies and to
achieve expected benefits, risks of third party claims alleging
infringement of patents and proprietary rights or seeking to
invalidate Twist Bioscience’s patents or proprietary rights; and
the risk that Twist Bioscience’s proprietary rights may be
insufficient to protect its technologies. For a further description
of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to Twist Bioscience’s business in general,
see Twist Bioscience’s risk factors set forth in Twist Bioscience’s
Annual Report Form 10-K filed with the Securities and Exchange
Commission on November 23, 2021, and subsequent filings with the
SEC. Any forward-looking statements contained in this press release
speak only as of the date hereof, and Twist Bioscience specifically
disclaims any obligation to update any forward-looking statement,
whether because of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211220005181/en/
Angela Bitting Twist Bioscience (925) 202-6211
abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024